An elevated serum level of endothelial monocyte activating polypeptide-II in patients with arterial hypertension with and without type 2 diabetes and obesity


Objectives: To assess serum levels of endothelial monocyte activating polypeptide-II (EMAP-II) in patients with arterial hypertension with and without type 2 diabetes mellitus and obesity.

Materials and methods: We examined 41 hypertensive patients with type 2 diabetes, 18 obese hypertensive patients without diabetes, 9 non-obese hypertensive patients without diabetes, and 18 healthy control subjects.

Results: We found an increased serum level of EMAP-II in hypertensive patients with type 2 diabetes compared to controls (4.86±2.3 and 1.08±0.53 ng/ml respectively, р<0.01), in hypertensive patients with obesity (2.92±1.42 ng/ml) compared to controls, and in non-obese hypertensive patients (2.02±0.33 ng/ml) compared to controls. Also, the levels of EMAP-II significantly correlated with HbA1c, blood glucose, serum insulin levels, HOMA, lipids, and body mass index (р<0.01).

Conclusions: The revealed changes could reflect an endothelial dysfunction mostly pronounced in patients with arterial hypertension, type 2 diabetes mellitus and obesity. Hyperglycemia, dyslipidemia, insulin resistance, obesity appear to be significant contributing factors leading to the elevation of EMAP-II.

About the authors

Liliya Mogylnytska

Khmelnytsky regional hospital, Ukraine

Author for correspondence.

Ukraine MD, PhD, endocrinologyst

Boris Mankovsky

P.L. Shupyk National Medical Academy of Postgraduate Education


Ukraine MD, PhD, prof.


  1. Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5·4 million participants. The Lancet. 2011;377(9765):568-577. doi: 10.1016/s0140-6736(10)62036-3.
  2. Standards of Medical Care in Diabetes--2014. Diabetes Care. 2013;37(Supplement_1):S14-S80. doi: 10.2337/dc14-S014.
  3. Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851-2906. doi: 10.1093/eurheartj/ehr211.
  4. DeMarco VG, Aroor AR, Sowers JR. The pathophysiology of hypertension in patients with obesity. Nature Reviews Endocrinology. 2014;10(6):364-376. doi: 10.1038/nrendo.2014.44.
  5. Kang YS. Obesity Associated Hypertension: New Insights into Mechanism. Electrolytes & Blood Pressure. 2013;11(2):46. doi: 10.5049/ebp.2013.11.2.46.
  6. Cremer A, Butlin M, Codjo L, et al. Determination of central blood pressure by a noninvasive method (brachial BP and QKD interval). J Hypertens. 2012;30(8):1533-1539. doi: 10.1097/HJH.0b013e328354dd26.
  7. Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA: The Journal of the American Medical Association. 2001;285(19):2486-2497. doi: 10.1001/jama.285.19.2486.
  8. van Horssen R, Eggermont AMM, ten Hagen TLM. Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. Cytokine Growth Factor Rev. 2006;17(5):339-348. doi: 10.1016/j.cytogfr.2006.08.001.
  9. Thompson JL, Ryan JA, Barr ML, et al. Potential role for antiangiogenic proteins in the myocardial infarction repair process. J Surg Res. 2004;116(1):156-164. doi: 10.1016/j.jss.2003.06.001.
  10. Yuan C, Yan L, Solanki P, et al. Blockade of EMAP II protects cardiac function after chronic myocardial infarction by inducing angiogenesis. J Mol Cell Cardiol. 2015;79:224-231. doi: 10.1016/j.yjmcc.2014.11.021.
  11. Tsai BM. Endothelial monocyte-activating polypeptide II causes NOS-dependent pulmonary artery vasodilation: a novel effect for a proinflammatory cytokine. AJP: Regulatory, Integrative and Comparative Physiology. 2004;287(4):R767-R771. doi: 10.1152/ajpregu.00248.2004.
  12. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. J Am Coll Cardiol. 2014;63(25):2935-2959. doi: 10.1016/j.jacc.2013.11.005.
  13. Mancia G, Fagard R, Narkiewicz K, et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens. 2013;31(10):1925-1938. doi: 10.1097/HJH.0b013e328364ca4c.
  14. Tocci G, Ferrucci A, Guida P, et al. An Analysis of the Management of Cardiovascular Risk Factors in Routine Clinical Practice in Italy. High Blood Press Cardiovasc Prev. 2011;18(1):19-30. doi: 10.2165/11588040-000000000-00000.
  15. Cockcroft J, Mancia G. Vascular aging. J Hypertens. 2012;30:S1-S2. doi: 10.1097/HJH.0b013e328353e4ec.
  16. Mohyl’nyts’ka LA. Serum Levels of Endothelial Monocyte-Activating Polypeptide-II in type 2 Diabetes Mellitus. Fiziol Zh. 2014;60(1):84-90.
  17. Adly AAM, Ismail EA, Tawfik LM, et al. Endothelial monocyte activating polypeptide II in children and adolescents with type 1 diabetes mellitus: Relation to micro-vascular complications. Cytokine. 2015;76(2):156-162. doi: 10.1016/j.cyto.2015.06.006.
  18. Mauricio M, Aldasoro M, Ortega J, Vila J. Endothelial Dysfunction in Morbid Obesity. Curr Pharm Des. 2013;19(32):5718-5729. doi: 10.2174/1381612811319320007.
  19. Grossman E, Messerli FH. Hypertension and diabetes. AdvCardiol 2008; 45: 82-106. doi: 10.1159/0000115189
  20. Bornfeldt Karin E, Tabas I. Insulin Resistance, Hyperglycemia, and Atherosclerosis. Cell Metab. 2011;14(5):575-585. doi: 10.1016/j.cmet.2011.07.015.
  21. Martín-Timón I. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5(4):444. doi: 10.4239/wjd.v5.i4.444.



Abstract - 1034

PDF (Russian) - 494



Copyright (c) 2016 Могильницькая Л.А., Маньковский Б.Н.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies